C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
C4 Therapeutics (Nasdaq: CCCC) announced the approval of an inducement grant consisting of non-qualified stock options to purchase 345,600 shares of common stock for one new employee. The grant, approved by independent directors on the Organization, Leadership and Compensation Committee, was made on October 28, 2024. The exercise price equals the closing price on the grant date. The options will vest over four years, with 25% vesting after one year and the remaining shares vesting in 36 monthly installments, contingent on continued employment.
C4 Therapeutics (Nasdaq: CCCC) ha annunciato l'approvazione di un contributo incentivante costituito da opzioni su azioni non qualificate per l'acquisto di 345.600 azioni di azioni ordinarie per un nuovo dipendente. Il contributo, approvato dai direttori indipendenti della Commissione Organizzazione, Leadership e Compensazione, è stato effettuato il 28 ottobre 2024. Il prezzo di esercizio corrisponde al prezzo di chiusura nella data di concessione. Le opzioni si attiveranno nel corso di quattro anni, con il 25% che si attiva dopo un anno e le azioni rimanenti che si attiveranno in 36 rate mensili, subordinato al mantenimento dell'impiego.
C4 Therapeutics (Nasdaq: CCCC) anunció la aprobación de una subvención de incentivo que consiste en opciones sobre acciones no calificadas para la compra de 345,600 acciones ordinarias para un nuevo empleado. La concesión, aprobada por directores independientes del Comité de Organización, Liderazgo y Compensación, se realizó el 28 de octubre de 2024. El precio de ejercicio es igual al precio de cierre en la fecha de concesión. Las opciones se otorgarán durante cuatro años, con el 25% otorgado después de un año y las acciones restantes otorgadas en 36 cuotas mensuales, condicionadas a la continuación del empleo.
C4 Therapeutics (Nasdaq: CCCC)는 한 신입 사원을 위해 유인 보상으로 구성된 비리미재 주식 옵션 345,600 주 구매의 승인을 발표했습니다. 이 보상은 조직, 리더십 및 보상위원회의 독립 이사에 의해 승인되었으며, 2024년 10월 28일에 이루어졌습니다. 행사가격은 보상 날짜의 종가와 동일합니다. 옵션은 4년 동안 만료됩니다, 1년 후에 25%가 만료되고 나머지 주식은 계속 고용되는 조건 하에 36개월에 걸쳐 만료됩니다.
C4 Therapeutics (Nasdaq: CCCC) a annoncé l'approbation d'un octroi d'incitation consistant en des options sur actions non qualifiées pour l'achat de 345 600 actions ordinaires pour un nouvel employé. L'octroi, approuvé par des administrateurs indépendants du Comité d'organisation, de leadership et de compensation, a été réalisé le 28 octobre 2024. Le prix d'exercice est égal au prix de clôture à la date de l'octroi. Les options seront acquises sur quatre ans, avec 25 % acquis après un an et les actions restantes acquises en 36 versements mensuels, sous condition de maintien de l'emploi.
C4 Therapeutics (Nasdaq: CCCC) gab die Genehmigung eines Belohnungszuschusses bekannt, der aus nicht qualifying Aktienoptionen zur Erwerbung von 345.600 Aktien des Stammkapitals für einen neuen Mitarbeiter besteht. Der Zuschuss, genehmigt von unabhängigen Direktoren des Ausschusses für Organisation, Führung und Vergütung, wurde am 28. Oktober 2024 genehmigt. Der Ausübungspreis entspricht dem Schlusskurs am Datum der Gewährung. Die Optionen werden über vier Jahre erlangt, wobei 25 % nach einem Jahr und die verbleibenden Aktien in 36 monatlichen Raten, abhängig von einer fortgesetzten Anstellung, erlangt werden.
- None.
- None.
WATERTOWN, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that the independent directors serving on the Organization, Leadership and Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase 345,600 shares of the Company’s common stock to one new employee (the “Inducement Grant”), with the grant made on October 28, 2024 (the “Grant Date”). The Inducement Grant was granted as a material inducement to this individual entering into employment with C4T in accordance with Nasdaq Listing Rule 5635(c)(4).
The Inducement Grant has an exercise price per share that is equal to the closing price of C4T’s common stock on the Grant Date. The Inducement Grant will vest over a four-year period, with
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com.
Contacts:
Investors:
Courtney Solberg
Senior Manager, Investor Relations
CSolberg@c4therapeutics.com
Media:
Loraine Spreen
Senior Director, Corporate Communications & Patient Advocacy
LSpreen@c4therapeutics.com
FAQ
What is the size of C4 Therapeutics (CCCC) inducement grant announced on October 28, 2024?
What are the vesting terms for C4 Therapeutics (CCCC) October 2024 inducement grant?
When was C4 Therapeutics (CCCC) inducement grant approved and under what rule?
